AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X

Find Drugs in Development News & Deals for R-Azasetron Besylate

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

0

Listed Suppliers

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Details:

SENS-401 (arazasetron) is an orally available 5-HT3 receptor antagonist, small molecule drug. It is being evaluated in phase 2 clinical trials for the treatment of hearing loss.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 11, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 (arazasetron) is an orally available 5-HT3 receptor antagonist, small molecule drug. It is being evaluated in phase 2 clinical trials for the treatment of hearing loss.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 01, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 (Arazasetron) is a 5-HT3 receptor antagonist and calcineurin inhibitor, orally available small molecule, which is under phase 2 clinical development for the treatment of Cisplatin-Induced Ototoxicity (CIO).


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 18, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 (R-azasetron besylate), is a 5-HT3 receptor antagonist and calcineurin inhibitor, orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 03, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 (arazasetron), is an orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 24, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 (Arazasetron) is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelae hearing impairment.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 14, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 (Arazasetron), is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 (R-azasetron besylate) is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 01, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 (R-azasetron Besylate) is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 07, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 is a first-in-class drug candidate to treat Sudden Sensorineural Hearing Loss, aiming at treating or protecting against inner ear lesions that lead to nerve degeneration and sensory hair cell loss.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 demonstrated a statistically significant effect with the high dose on pure tone audiometry (≥ 10 decibels improvement vs placebo) in Phase 2 AUDIBLE-S trial in SSNHL at Day 84 in per protocol idiopathic population (81 patients) treated with corticosteroids.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 17, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 (R-azasetron besylate), oral small molecule lead asset currently being investigated in sudden sensorineural hearing loss and cisplatin-induced ototoxicity aims to protect and preserve inner ear tissue from damage.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Association for Research in Otolaryngology

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 03, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 (Arazasetron), is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Cochlear Limited

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 27, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The poster presented shows SENS-401 ability to yield significant treatment benefits in rats with severe hearing loss when initiated with a delay up to 7 days after the initial acoustic trauma.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 19, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY